Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 3/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29981118 | 1.00 | UCHL1 (0.35) | UCHL1DRD1PTGDRIDH1ADRA2A | |
| SCHEMBL29981159 | 1.00 | UCHL1 (0.35) | UCHL1DRD1PTGDRIDH1ADRA2A | |
| SCHEMBL19821177 | 1.00 | UCHL1 (0.35) | UCHL1DRD1PTGDRIDH1ADRA2A | |
| SCHEMBL20700266 | 0.95 | UCHL1 (0.36) | UCHL1PTGDRIDH1ADRA2AADRA2B | |
| SCHEMBL30030579 | 0.87 | HTR2C (0.34) | DRD1PTGDRIDH1ADRA2AADRA2B | |
| SCHEMBL30030424 | 0.87 | HTR2C (0.34) | DRD1PTGDRIDH1ADRA2AADRA2B | |
| SCHEMBL19821161 | 0.87 | HTR2C (0.34) | DRD1PTGDRIDH1ADRA2AADRA2B | |
| SCHEMBL30029677 | 0.87 | HTR2C (0.34) | DRD1PTGDRIDH1ADRA2AADRA2B | |
| SCHEMBL19821159 | 0.87 | HTR2C (0.34) | DRD1PTGDRIDH1ADRA2AADRA2B | |
| SCHEMBL19821160 | 0.87 | HTR2C (0.34) | DRD1PTGDRIDH1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388558-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250304546-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4593954-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI Drug Discovery LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250243173-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250236602-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250129035-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2024073383-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11491133-B2 | Heteroaryl-isochroman compounds and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129035-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | UCHL1 2325/4885DRD1 1222/4885PTGDR 606/4885 |
| US-20250236602-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | UCHL1 2325/4885DRD1 1222/4885PTGDR 606/4885 |
| US-20250304546-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | UCHL1 2325/4885DRD1 1222/4885PTGDR 606/4885 |
| US-20250243173-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | UCHL1 2325/4885DRD1 1222/4885PTGDR 606/4885 |
| US-20250388558-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | GRIN2C, SLC6A1, CLIC1 | UCHL1 2633/4885DRD1 527/4885PTGDR 1749/4885 |
| US-11491133-B2 | Heteroaryl-isochroman compounds and uses thereof | GRIN2C, INA, SDHA | UCHL1 1171/4885DRD1 1458/4885PTGDR 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.